ACTRN12617000438358已完成未知
Cancer Care: The risk factors of venous access failure. A prospective observational study of peripheral and central venous catheter outcomes among adult patients within a tertiary care setting.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •(1) Cancer Care Services inpatient
- •(2) Patient able to provide informed consent
- •(3) PVC inserted within 48hours of admission
排除标准
- •(1) Patients who are on a care of the dying pathway
- •(2) Non-English speaking background (NESB) without an available interpreter
- •(3) Previous enrolment in the study
研究者
相似试验
进行中（未招募）
1 期
ong-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisEUCTR2017-003342-25-PLASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722
进行中（未招募）
1 期
ong-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisEUCTR2017-003342-25-GBASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722
招募中
3 期
ong-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisNL-OMON54840Assistance Publique-Hôpitaux de Paris (APHP) delegated to Recherche Clinique et à lInnovation (DRCI)110
进行中（未招募）
1 期
ong-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisAny cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intra-cerebral metastasis) with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, afterat least 6 months of anticoagulant therapy for the treatment of the index event, with no objectively documented symptomatic recurrence of VTE between the index event and randomization.MedDRA version: 21.1Level: LLTClassification code 10076654Term: Cancer-associated thrombosisSystem Organ Class: 100000004864EUCTR2017-003342-25-NLASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722
进行中（未招募）
1 期
ong-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisAny cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intra-cerebral metastasis) with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after at least 6 months of anticoagulant therapy for the treatment of the index event, with no objectively documented symptomatic recurrence of VTE between the index event and randomization.MedDRA version: 20.0Level: LLTClassification code 10076654Term: Cancer-associated thrombosisSystem Organ Class: 100000004864EUCTR2017-003342-25-ESASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722